Basic Information
ProteoMediX specializes in the identification of novel biomarkers for early cancer detection and personalized treatment. The first product currently under development is a blood-based test that can diagnose prostate cancer with higher accuracy than current clinical standards. This product reduces unnecessary biopsies, significantly saving costs for the healthcare system and minimizing patient discomfort.
Proteomedix AG
Zurich,Switzerland
unclear
March 01, 2010
contact@proteomedix.com

